Posted by admin on May 5th, 2022
CorMedix (NYSE:CRMD – Get Rating) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, May 12th. Analysts expect CorMedix to post earnings of ($0.23) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.
Shares of CRMD stock opened at $3.61 on Thursday. CorMedix has a 12 month low of $3.32 and a 12 month high of $8.70. The firm has a market cap of $139.81 million, a PE ratio of -4.88 and a beta of 2.39.
Separately, StockNews.com upgraded shares of CorMedix to a “sell” rating in a report on Thursday, April 14th.
CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology.
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
Medicenna Therapeutics (TSE:MDNA) Coverage Initiated by Analysts at Maxim Group
Aurora Cannabis (ACB) Set to Announce Quarterly Earnings on Thursday